Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 8, 2014, Pages 631-641

  De Kam, Pieter Jan ^a   Kruithof, Annelieke C ^b   Van Lierop, Marie José ^a   Moerland, Matthijs ^b   Dennie, Justin ^a   Troyer, Matthew D ^a   Langdon, Ronald B ^a   Gutstein, David E ^a   Burggraaf, Jacobus ^b   El Galta, Rachid ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

Neuromuscular blockade; Rocuronium; Surgical thromboprophylaxis; Vecuronium; cyclodextrin

Indexed keywords

ADOLESCENT; ADULT; ANTICOAGULANTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENOXAPARIN; FACTOR XA; GAMMA-CYCLODEXTRINS; HEPARIN; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; YOUNG ADULT;

EID: 84905841262     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202091     Document Type: Article

References (22)

1. Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, Palin R, Prosser A, Rees DC, Rosair GM, Stevenson D, Tarver GJ, Zhang MQ. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem. 2002; 45: 1806-1816. CrossRef PubMed (Pubitemid 34415376)
2. Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs. 2009; 69: 919-942. CrossRef PubMed
3. European Medicines Agency. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000885/WC500052310.pdf. Accessed April 15, 2013.
4. De Kam PJ, Grobara P, Prohn M, Höppener F, Kluft C, Burggraaf J, Langdon RB, Peeters P. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. Int J Clin Pharmacol Ther. 2014; 52: 227-236. PubMed
5. de Kam PJ, El Galta R, Kruithof AC, Fennema H, Mihara K, Burggraaf J, Moerland M, Peeters P, Troyer MD. No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters. Int J Clin Pharmacol Ther. 2013; 51; 976-985.
6. Rahe-Meyer N, Fennema H, Schulman S, Klimscha W, Przemeck M, Blobner M, Wulf HF, Speek M, Sisk CM, Williams-Herman DA, Woo T, Szegedi A. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk. Anesthesiology. Submitted.
7. Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol. 1988; 28: 609-618. CrossRef PubMed (Pubitemid 19013395)
8. Carter CA, Skoutakis VA, Spiro TE, West ME, Tooms RE, Joe RH, Knutson TJ. Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. Ann Pharmacother. 1993; 27: 1223-1230. PubMed (Pubitemid 23321973)
9. Fareed J, Hoppensteadt D, Walenga J, Iqbal O, Ma Q, Jeske W, Sheikh T. Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. Clin Pharmacokinet. 2003; 42: 1043-1057. CrossRef PubMed (Pubitemid 37186676)
10. Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin. J Clin Pharmacol. 2008; 48: 1189-1196. CrossRef PubMed
11. Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JM, Harthoorn-Lasthuizen EJ, Schoemaker HC, van der Meer FJ, Cohen AF. Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation. 1992; 86: 1370-1375. CrossRef PubMed
12. Kearon C, Harrison L, Crowther M, Ginsberg JS. Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis. Thromb Res. 2000; 97: 395-403. CrossRef PubMed (Pubitemid 30125705)
13. LOVENOX [Prescribing Information]. http://products.sanofi.us/lovenox/ lovenox.html. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2013. Accessed October 17, 2013.
14. Society of American Gastrointestinal and Endoscopic Surgeons. Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Website. Guidelines for deep venous thrombosis prophylaxis during laparoscopic surgery. http://www.sages.org/publications/guidelines/guidelines-for-deep-venous- thrombosis-prophylaxis-during-laparoscopic-surgery. Accessed July 03, 2013.
15. de Zwart MA, ten Bruggencate-Broeders J, van Hal HJ, Megens RH, Frasa HW. Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879: 1573-1586. CrossRef PubMed
16. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995; 333: 11-17. CrossRef PubMed
17. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med. 1996; 335: 540-546. CrossRef PubMed (Pubitemid 26272308)
18. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; 2006 Writing Committee Members; American College of Cardiology/American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008; 118: e523-e661. PubMed
19. Blann AD, Khoo CW. The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. Vasc Health Risk Manag. 2009; 5: 693-704. CrossRef PubMed
20. Staals LM, Snoeck MM, Driessen JJ, van Hamersvelt HW, Flockton EA, van den Heuvel MW, Hunter JM. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010; 104: 31-39. CrossRef PubMed
21. Kleijn HJ, Zollinger DP, van den Heuvel MW, Kerbusch T. Population pharmacokinetic-pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. Br J Clin Pharmacol. 2011; 72: 415-433. CrossRef PubMed
22. Peeters PA, van den Heuvel MW, van Heumen E, Passier PC, Smeets JM, van Iersel T, Zwiers A. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig. 2010; 30: 867-874. CrossRef PubMed